Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs

217Citations
Citations of this article
137Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Reactivation of mutant p53 is likely to provide important benefits for treatment of chemotherapy- and radiotherapy-resistant tumors. We demonstrate here that the maleimide-derived molecule MIRA-1 can reactivate DNA binding and preserve the active conformation of mutant p53 protein in vitro and restore transcriptional transactivation to mutant p53 in living cells. MIRA-1 induced mutant p53-dependent cell death in different human tumor cells carrying tetracycline-regulated mutant p53. The structural analog MIRA-3 showed antitumor activity in vivo against human mutant p53-carrying tumor xenografts in SCID mice. The MIRA scaffold is a novel lead for the development of anticancer drugs specifically targeting mutant p53. © 2005 by The American Society for Biochemistry and Molecular Biology, Inc.

Cite

CITATION STYLE

APA

Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., … Wiman, K. G. (2005). Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. Journal of Biological Chemistry, 280(34), 30384–30391. https://doi.org/10.1074/jbc.M501664200

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free